JP2016534996A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534996A5
JP2016534996A5 JP2016523209A JP2016523209A JP2016534996A5 JP 2016534996 A5 JP2016534996 A5 JP 2016534996A5 JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016534996 A5 JP2016534996 A5 JP 2016534996A5
Authority
JP
Japan
Prior art keywords
patient
administration
antigen
binding fragment
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016523209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/060432 external-priority patent/WO2015057668A1/en
Publication of JP2016534996A publication Critical patent/JP2016534996A/ja
Publication of JP2016534996A5 publication Critical patent/JP2016534996A5/ja
Pending legal-status Critical Current

Links

JP2016523209A 2013-10-15 2014-10-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 Pending JP2016534996A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US61/891,175 2013-10-15
US201461970126P 2014-03-25 2014-03-25
US61/970,126 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019132432A Division JP6870037B2 (ja) 2013-10-15 2019-07-18 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法

Publications (2)

Publication Number Publication Date
JP2016534996A JP2016534996A (ja) 2016-11-10
JP2016534996A5 true JP2016534996A5 (OSRAM) 2017-11-16

Family

ID=52809872

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016523209A Pending JP2016534996A (ja) 2013-10-15 2014-10-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2019132432A Active JP6870037B2 (ja) 2013-10-15 2019-07-18 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2021068065A Pending JP2021107421A (ja) 2013-10-15 2021-04-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019132432A Active JP6870037B2 (ja) 2013-10-15 2019-07-18 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2021068065A Pending JP2021107421A (ja) 2013-10-15 2021-04-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法

Country Status (12)

Country Link
US (4) US20150104447A1 (OSRAM)
EP (2) EP3485902A1 (OSRAM)
JP (3) JP2016534996A (OSRAM)
KR (1) KR20160061352A (OSRAM)
CN (2) CN113230399A (OSRAM)
AU (2) AU2014334563A1 (OSRAM)
BR (1) BR112016008082A2 (OSRAM)
CA (1) CA2925402A1 (OSRAM)
MX (2) MX2016004329A (OSRAM)
RU (1) RU2706729C2 (OSRAM)
SG (2) SG10201807318RA (OSRAM)
WO (1) WO2015057668A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
WO2015107015A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
CA3160521A1 (en) * 2019-12-06 2021-06-10 Sanofi Biotechnology Methods for treating copd by administering an il-33 antagonist
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
CA3223191A1 (en) * 2021-09-03 2023-03-09 University Of Utah Research Foundation Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3946256B2 (ja) 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン５受容体α鎖に対する抗体
WO2000061739A1 (fr) * 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2001060405A1 (en) * 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2008143878A1 (en) * 2007-05-14 2008-11-27 Medimmune, Llc Methods of reducing eosinophil levels
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
HUE034005T2 (en) * 2010-10-15 2018-01-29 Medimmune Ltd Therapies for improving lung function
EP3447491A3 (en) * 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
PL3033104T3 (pl) * 2013-08-12 2019-09-30 Astrazeneca Ab Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu
PL3033101T3 (pl) * 2013-08-12 2019-06-28 Astrazeneca Ab Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu
CA2918050C (en) * 2013-08-12 2023-10-03 Medimmune, Llc Methods for improving asthma symptoms using benralizumab

Similar Documents

Publication Publication Date Title
JP2016534996A5 (OSRAM)
Lugogo et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study
Thibodeaux et al. A review of dupilumab in the treatment of atopic diseases
Mukherjee et al. Anti-IL5 therapy for asthma and beyond
Dahl et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study
Wedzicha et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients
JP2016513640A5 (OSRAM)
JP2022120009A (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
Fala Ofev (Nintedanib): first tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis
JP2016515124A5 (OSRAM)
Mkorombindo et al. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
Saco et al. Benralizumab for the treatment of asthma
Hanania et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD
Donohue et al. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD
Sadigursky et al. Effect of tranexamic acid on bleeding control in total knee arthroplasty
JP2014520874A5 (OSRAM)
JP2014513121A5 (OSRAM)
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
Mathioudakis et al. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
JP2013525310A5 (OSRAM)
JP2017514829A5 (OSRAM)
Black et al. Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
RU2013126798A (ru) Комбинированная терапия дексаметазоном
Bayoumi-Ali et al. Drugs That Act on the Respiratory Tract